Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2012 June;64(2) > Minerva Urologica e Nefrologica 2012 June;64(2):79-88

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA UROLOGICA E NEFROLOGICA

A Journal on Nephrology and Urology


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,984


eTOC

 

  ADVANCES IN UROLOGY


Minerva Urologica e Nefrologica 2012 June;64(2):79-88

Copyright © 2012 EDIZIONI MINERVA MEDICA

language: English

Surgeon controlled robot-assisted laparoscopic radical cystectomy: current review of oncologic and functional outcomes

Mckenzie P. L., Hemal A. K.

Department of Urology Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA


PDF  


Surgeon controlled robot-assisted laparoscopic radical cystectomy (RARC) is becoming a viable treatment option for patients with muscle-invasive bladder cancer. There are currently several single-institution reports and a few multi-intitutional reports on operative, perioperative, and intermediate-term oncologic outcomes for RARC. While the data appears promising, there is currently no long term oncologic outcomes for RARC. Long-term oncologic outcomes for RARC should be forthcoming in the near future. As the technology improves, and surgeons become more proficient at RARC, the cost effectiveness of RARC should surpass open radical cystectomy. The goal of this article is to review the most recent developments within the past 1 to 2 years surrounding RARC, including important technical advances for performing this operation, current data on oncologic outcomes, and the future direction of RARC.

top of page

Publication History

Cite this article as

Corresponding author e-mail

pmckenzi@wakehealth.edu